女性与男性择期Ovation支架EVAR术后5年结局相似
基于ENCORE数据库(5项试验及欧洲上市后注册)1045例男性与251例女性患者,比较择期Ovation支架腔内修复肾下腹主动脉瘤的5年结局;女性近端瘤颈解剖更不利,但两组IA型内漏、I/III型内漏、再干预及生存率均无显著差异。
要点
- 女性近端瘤颈更短、成角更大、反向锥形比例更高,但5年IA型内漏率与男性相似(96% vs 97%)。
- 女性5年免于I/III型内漏为94%,再干预为93%,与男性无显著差异。
- 女性5年生存率81%,男性79%,性别不是不良结局的独立危险因素。
核心结论
- 女性EVAR术前近端瘤颈解剖更不利,但Ovation支架术后5年内漏、再干预及生存结局与男性相似。
研究设计与样本
- 基于ENCORE数据库(含5项试验及欧洲上市后注册)的前瞻性数据,纳入1045例男性(81%)和251例女性(19%)择期EVAR患者。
- 比较男女近端瘤颈及髂动脉解剖特征,采用Kaplan-Meier法和log-rank检验评估5年结局,Cox比例风险模型校正基线差异。
主要发现
- 女性年龄更大(平均75±8.4岁 vs 73±8.1岁,P<.006),动脉瘤直径更小(52±7.5 mm vs 55±9.2 mm,P<.001),近端瘤颈直径更小(21±3.3 mm vs 23±2.9 mm,P<.001)。
- 校正体表面积后,女性动脉瘤及瘤颈相对更大,且近端瘤颈更短、髂动脉直径更小、成角更大、反向锥形比例更高。
- 5年免于IA型内漏(96% vs 97%,P=.38)、I/III型内漏(94% vs 91%,P=.37)、再干预(93% vs 91%,P=.67)及生存率(81% vs 79%,P=.55)均无显著性别差异。
- 动脉瘤相关死亡女性1例(0.4%),男性5例(0.8%,P=.76)。
- 校正后性别与IA型内漏(HR 1.4,95%CI 0.6-3.1,P=.41)、I/III型内漏(HR 1.4,95%CI 0.7-2.8,P=.33)、再干预(HR 1.0,95%CI 0.6-2.0,P=.77)及总死亡率(HR 0.7,95%CI 0.4-1.1,P=.14)均无关联。
临床怎么用
- 对于近端瘤颈解剖不利的女性肾下腹主动脉瘤患者,Ovation支架可作为择期EVAR的可行选择。
- 女性患者EVAR术后5年内漏及再干预风险与男性相当,无需仅因性别而改变随访或再干预策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Female patients undergoing endovascular aneurysm repair (EVAR) for infrarenal abdominal aortic aneurysms present with more challenging anatomy and historically have worse outcomes compared with men. The Ovation Abdominal Stent Graft platform (Endologix, Irving, Calif) contains a polymer-filled proximal sealing ring and has a low-profile delivery system, potentially beneficial in female patients. We therefore investigated differences in long-term outcomes between men and women treated with this device. METHODS: We used data collected prospectively in the Effectiveness of Custom Seal with Ovation: Review of the Evidence (ENCORE) database, comprising five trials and the European Post-Market Registry. Anatomic characteristics of the proximal aneurysm neck and iliac arteries were compared between male and female patients. Outcomes were 5-year freedom from type IA and type I/III endoleaks, abdominal aortic aneurysm-related reinterventions, and overall survival. We used Kaplan-Meier analysis to estimate survival proportions and tested univariate differences in survival using log-rank tests. Cox proportional hazards modeling was used to adjust for baseline differences. RESULTS: We identified 1045 (81%) male and 251 (19%) female patients undergoing EVAR. Female patients were older (mean age, 75 ± 8.4 years vs 73 ± 8.1 years; P < .006). Aneurysm diameter (52 ± 7.5 mm vs 55 ± 9.2 mm; P < .001) and proximal neck diameter (21 ± 3.3 mm vs 23 ± 2.9 mm; P < .001) were smaller in female patients, but adjusted for body surface area, female patients had relatively larger aneurysms and aneurysm necks. Furthermore, female patients presented with shorter proximal necks, smaller iliac artery diameters, more angulated necks, and higher rates of reverse-tapered necks. Five-year freedom from type IA endoleak was similar between men and women (97% vs 96%; P = .38), as was freedom from type I/III endoleaks (91% vs 94%; P = .37) and reinterventions (91% vs 93%; P = .67). Five-year survival was 81% for female patients, similar to the 79% in male patients (P = .55), with one aneurysm-related death in female patients (0.4%) and five in male patients (0.8%; P = .76). Risk-adjusted analyses showed no association between sex and type IA endoleak (hazard ratio [HR], 1.4; 95% confidence interval [CI], 0.6-3.1; P = .41), type I/III endoleak (HR, 1.4; 95% CI, 0.7-2.8; P = .33), reintervention (HR, 1.0; 95% CI, 0.6-2.0; P = .77), and overall mortality (HR, 0.7; 95% CI, 0.4-1.1; P = .14). CONCLUSIONS: Female patients undergoing EVAR with the Ovation platform presented with substantially more adverse proximal neck characteristics. Despite these differences, 5-year freedom from endoleaks and overall survival did not differ between sexes.
引用
- Varkevisser RRB, Swerdlow NJ, Verhagen HJM, et al. Similar 5-year outcomes between female and male patients undergoing elective endovascular abdominal aortic aneurysm repair with the Ovation stent graft. J Vasc Surg. 2019. PMID: 31843301. doi:10.1016/j.jvs.2019.08.275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。